In addition, for patients with BRAFV600E-mutated biliary tract cancer, dual blockade of both BRAF (dabrafenib) and MEK (trametinib) have been considered as a promising treatment option from a phase 2, open-label, single-arm, multicenter basket trial [39]. This evidence concerns the gene MAP2K7 and biliary tract neoplasm.